Company:  INCYTE CORP (INCY)
Form Type:  8-K
Filing Date:  10/27/2011 
CIK:  0000879169 
Address:  ROUTE 141 & HENRY CLAY ROAD
BUILDING E336
 
City, State, Zip:  WILMINGTON, Delaware 19880 
Telephone:  (302) 498-6700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$47.30  
Change: 
0.34 (0.72%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$7.83B
Description of Business
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. We have a broad pipeline with programs focused primarily in the areas of oncology and inflammation. We focus our efforts on clinical programs that we believe have the greatest likelihood of creating near-and long-term value and on compounds that we believe a company of our size can effectively develop and commercialize on its own, or that we can further develop and commercialize through strategic relationships. Our highest priority programs involve our janus kinase (JAK) inhibitors, which include oral INCB18424 for hematologic and oncology indications and oral INCB28050 for chronic inflammatory and autoimmune diseases.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02 Results of Operations and ...
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and ...
    SIGNATURE
  EXHIBIT 99.1
    INCOME STATEMENT
BROKERAGE PARTNERS